ArticleAntimicrobial agents and chemotherapy2014
An altered Mycobacterium tuberculosis metabolome induced by katG mutations resulting in isoniazid resistance.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 45 citations in OpenAlex.
- Exploratory investigation of urinary alkanes and other volatile organic compounds in paediatric patients with tuberculous meningitis.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Differential producibility analysis reveals drug-associated carbon and nitrogen metabolite expressions in Mycobacterium tuberculosis.The Journal of biological chemistry · 2025Article
- New volatile organic compounds from the exhaled breath of active tuberculosis patients.Scientific reports · 2025Article
- Whole genome CRISPRi screening identifies druggable vulnerabilities in an isoniazid resistant strain of Mycobacterium tuberculosis.Nature communications · 2024Article
- The metabolic consequences of HIV/TB co-infection.BMC infectious diseases · 2023Article
- Comprehensive Two-Dimensional Gas Chromatography as a Bioanalytical Platform for Drug Discovery and Analysis.Pharmaceutics · 2023Review
- M. tuberculosis AlkX Encoded byMicrobiology spectrum · 2022Article
- Elucidating the Antimycobacterial Mechanism of Action of Ciprofloxacin Using Metabolomics.Microorganisms · 2021Article
- Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis.Molecules (Basel, Switzerland) · 2020Review
- Mycobacterium tuberculosis curli pili (MTP) deficiency is associated with alterations in cell wall biogenesis, fatty acid metabolism and amino acid synthesis.Metabolomics : Official journal of the Metabolomic Society · 2020Article
- Vitamin B and Vitamin C Affect DNA Methylation and Amino Acid Metabolism inFrontiers in microbiology · 2020Article
- [Mass spectrometry-based identification of new serum biomarkers in patients with multidrug resistant pulmonary tuberculosis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2019Article
- Review
- Dormant Mycobacterium tuberculosis converts isoniazid to the active drug in a Wayne's model of dormancy.The Journal of antibiotics · 2018Article
- Panomics for Precision Medicine.Trends in molecular medicine · 2018Review
- Emerging Approaches to Tuberculosis Drug Development: At Home in the Metabolome.Trends in pharmacological sciences · 2017Review
- Metabolomics: Applications and Promise in Mycobacterial Disease.Annals of the American Thoracic Society · 2015Review
- Mycobacterium tuberculosis metabolism.Cold Spring Harbor perspectives in medicine · 2014Review
- The use of functional genomics in conjunction with metabolomics for Mycobacterium tuberculosis research.Disease markers · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common form of drug resistance found in tuberculosis (TB)-positive clinical samples is monoresistance to isoniazid. Various genomics and proteomics studies to date have investigated this phenomenon; however, the exact mechanisms relating to how this occurs, as well as the implications of this on the TB-causing organisms function and structure, are only partly understood. Considering this, we followed a metabolomics research approach to identify potential new metabolic pathways and metabolite markers, which when interpreted in context would give a holistic explanation for many of the phenotypic characteristics associated with a katG mutation and the resulting isoniazid resistance in Mycobacterium tuberculosis. In order to achieve these objectives, gas chromatography-time of flight mass spectrometry (GCxGC-TOFMS)-generated metabolite profiles from two isoniazid-resistant strains were compared to a wild-type parent strain. Principal component analyses showed clear differentiation between the groups, and the metabolites best describing the separation between these groups were identified. It is clear from the data that due to a mutation in the katG gene encoding catalase, the isoniazid-resistant strains experience increased susceptibility to oxidative stress and have consequently adapted to this by upregulating the synthesis of a number of compounds involved in (i) increased uptake and use of alkanes and fatty acids as a source of carbon and energy and (ii) the synthesis of a number of compounds directly involved in reducing oxidative stress, including an ascorbic acid degradation pathway, which to date hasn't been proposed to exist in these organisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.